Joanne Curley - May 31, 2022 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Chief Development Officer
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
May 31, 2022
Transactions value $
-$3,537
Form type
4
Date filed
6/2/2022, 04:06 PM
Previous filing
Mar 3, 2022
Next filing
Jun 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $2.55K +400 +1.59% $6.37 25.6K May 31, 2022 Direct F1
transaction VERA Class A Common Stock Sale -$6.09K -400 -1.56% $15.22 25.2K May 31, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Options Exercise $0 -400 -1.54% $0.00 25.5K May 31, 2022 Class A Common Stock 400 $6.37 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,461 shares acquired under the Issuer's Employee Stock Purchase Plan on March 11, 2022.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022.
F3 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.10 to $15.53, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter.